UGT1A1Your two copies: *1/*28+*60+*80
Intermediate metabolizer
One copy works and one works less well.
Clears bilirubin and some drugs, such as the cancer drug irinotecan.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Oncology · ChemotherapiesExample report
Nilotinib
Tasigna
Use as directed
Your UGT1A1 result means somewhat lower UGT1A1 activity than usual, but the FDA gives no genetic dosing change for nilotinib at this result.
The genes behind this label
The guidelines read one gene for nilotinib. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
UGT1A1Intermediate metabolizer
- In plain words
- Your UGT1A1 result means somewhat lower UGT1A1 activity than usual, but the FDA gives no genetic dosing change for nilotinib at this result.
- What it means
- No FDA guidance for your genotype
- What the label suggests
- Initiate therapy with recommended starting dose.
About nilotinib
Nilotinib is a twice-daily oral treatment for Philadelphia chromosome-positive chronic myeloid leukemia (CML), sold as Tasigna capsules and as other nilotinib products.
- Used for
- Philadelphia chromosome-positive CML: newly diagnosed chronic phase, and chronic or accelerated phase after resistance or intolerance to earlier treatment
Others in oncology
Compare all 13 oncology- BelinostatBeleodaq Use as directed
- BelzutifanWelireg Use as directed
- CapecitabineXeloda, Xitabin, Kapetral Use as directed
- ErdafitinibBalversa Use as directed
- FluorouracilAdrucil, Carac Use as directed
- GefitinibIressa Use with caution
- IrinotecanCamptosar, Onivyde Use as directed
- MercaptopurinePurinethol Use as directed
Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.